FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979579528> ?p ?o ?g. }

• W2979579528 abstract "Abstract Abstract 3724 Poster Board III-660 Lymphomas account for about 5% of all cases of cancer in the US. In 2009, it is estimated that 74490 Americans will be diagnosed with lymphoma, which includes approximately 8510 new cases of Hodgkin's lymphoma and 65980 new cases of non-Hodgkin's lymphoma (NHL). An estimated 20790 men and women will die from lymphoma in 2009, the majority (93.8%) of which from NHL. Standard treatment includes chemotherapy and radiation to destroy the malignant lymphoma cells; however, newer therapies are currently being explored. Bortezomib is approved for multiple myeloma and relapsed mantle cell lymphoma, and is under clinical investigation in other types of NHL and other B-cell malignancies. Similar to bortezomib, MLN9708 is a modified dipeptidyl boronic acid that is a potent, reversible and specific inhibitor of the proteasome. MLN9708 preferentially binds to and inhibits b5 enzymatic activity of the 20S catalytic core. It is currently in Phase I trials for the treatment of solid and hematologic malignancies. MLN9708 immediately hydrolyzes to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 was used for all preclinical studies described below. We evaluated the ability of MLN2238 to inhibit tumor growth in two preclinical models of diffuse large B-cell lymphoma (DLBCL), an aggressive lymphoma that accounts for ∼40% of lymphomas in adults. OCI-LY10 and PHTX-22L are two examples of ABC-subtype of DLBCL. The antitumor activity of MLN2238 was evaluated in CB-17 Scid female mice bearing OCI-LY10 lymphoma xenografts. Tumor inhibition was determined by calculating the treatment over control (T/C) ratio of the mean tumor volume and the percentage of tumor growth inhibition (TGI) on the last day of the study. MLN2238 administered intravenous (IV) at 18 mg/kg once weekly (QW) resulted in tumor regression in 6 of 7 animals (T/C = 0.12; TGI = 88%) and a partial response in the remaining animal (43% reduction in tumor volume). MLN2238 administered at 8 mg/kg or 4 mg/kg IV QW resulted in a T/C of 0.42 and 0.36. Proteasome activity in the tumor was inhibited 49 and 44% 1 hour after a single IV dose of MLN2238 at 14 or 7 mg/kg, respectively. The other tumor model, PHTX-22L, is a primary tumor xenograft that was derived from a tumor surgically removed from the right lymph node of a 71-year-old Caucasian male. SCID NOD female mice implanted with PHTX-22L tumor fragments were treated twice weekly (BIW) with IV doses of vehicle, MLN2238 at 4 mg/kg SC once daily (QD), MLN2238 at 14 mg/kg IV BIW or bortezomib at 0.8 mg/kg IV BIW. The strongest antitumor activity was seen in PHTX-22L tumor bearing mice treated with IV MLN2238 14 mg/kg BIW (T/C = 0.14; TGI = 86%, p < 0.001) or SC MLN2238 4 mg/kg QD (T/C = 0.15; TGI = 85%, p < 0.01). These dosing regimens significantly inhibited tumor growth compared with vehicle treatment. In the same study, bortezomib treatment IV at 0.8 mg/kg on a BIW schedule had no antitumor effect (T/C = 0.88; TGI = 12%, p = 0.86) and was not statistically different from the vehicle treated group. Proteasome activity was significantly inhibited in both blood and tumor following a single dose of MLN2238 administered IV at 14 mg/kg or SC at 4 mg/kg. Proteasome activity was inhibited greater than 50% for up to 8 hrs following the IV dose in both blood and tumor, whereas proteasome activity recovered more quickly following the SC dose. In a separate preclinical study, the antitumor activity of MLN2238 administered at lower doses and on alternate schedules was examined. SCID NOD mice bearing PHTX-22L xenografts were administered MLN2238 IV at 11 mg/kg BIW, 7 mg/kg BIW, 11 mg/kg QW or 5 mg/kg QDx2/week resulted in significant antitumor activity (T/C = 0.04, 0.08, 0.15, 0.16; TGI = 96, 92, 85, 84%, respectively). More importantly, drug treatment caused tumor regression (tumor volume at the end of the study was less than 50% of the starting tumor volume) in 8 of 10 mice in the 11 mg/kg BIW, 5/10 in the 7 mg/kg BIW, 2/8 in the 11 mg/kg QW and 1/10 in the 5 mg/kg QDx2/week treatment groups. The efficacy of MLN2238 dosed IV either at 7 mg/kg QW or 3.5 mg/kg BIW in this model was less efficacious (T/C = 0.61 and 0.64). In addition to PHTX-22L, we have access to several other primary lymphoma tumor xenograft models that we plan to evaluate for sensitivity to MLN2238 treatment. These studies demonstrate that MLN2238 is active in preclinical models of lymphoma, and that MLN2238 has antitumor activity in a model of lymphoma that is refractory to bortezomib treatment. Disclosures: Donelan: Milllennium: Employment. Bannerman:Milllennium: Employment. Bano:Milllennium: Employment. Babcock:Milllennium: Employment. Hales:Millennium Pharmaceuticals: Employment. Stringer:Milllennium: Employment. Burke:Milllennium: Employment. Danaee:Milllennium: Employment, Equity Ownership. Faron-Yowe:Milllennium: Employment. Koenig:Milllennium: Employment. Lichter:Milllennium: Employment. Kupperman:Milllennium: Employment." @default.
• W2979579528 created "2019-10-18" @default.
• W2979579528 creator A5002916676 @default.
• W2979579528 creator A5007358069 @default.
• W2979579528 creator A5021962565 @default.
• W2979579528 creator A5022742969 @default.
• W2979579528 creator A5023536891 @default.
• W2979579528 creator A5024304750 @default.
• W2979579528 creator A5026551753 @default.
• W2979579528 creator A5027942543 @default.
• W2979579528 creator A5046196028 @default.
• W2979579528 creator A5063312525 @default.
• W2979579528 creator A5068055759 @default.
• W2979579528 creator A5083951467 @default.
• W2979579528 date "2009-11-20" @default.
• W2979579528 modified "2023-10-01" @default.
• W2979579528 title "Antitumor Activity of MLN9708, a Second-Generation Proteasome Inhibitor, in Preclinical Models of Lymphoma." @default.
• W2979579528 doi "https://doi.org/10.1182/blood.v114.22.3724.3724" @default.
• W2979579528 hasPublicationYear "2009" @default.
• W2979579528 type Work @default.
• W2979579528 sameAs 2979579528 @default.
• W2979579528 citedByCount "0" @default.
• W2979579528 crossrefType "journal-article" @default.
• W2979579528 hasAuthorship W2979579528A5002916676 @default.
• W2979579528 hasAuthorship W2979579528A5007358069 @default.
• W2979579528 hasAuthorship W2979579528A5021962565 @default.
• W2979579528 hasAuthorship W2979579528A5022742969 @default.
• W2979579528 hasAuthorship W2979579528A5023536891 @default.
• W2979579528 hasAuthorship W2979579528A5024304750 @default.
• W2979579528 hasAuthorship W2979579528A5026551753 @default.
• W2979579528 hasAuthorship W2979579528A5027942543 @default.
• W2979579528 hasAuthorship W2979579528A5046196028 @default.
• W2979579528 hasAuthorship W2979579528A5063312525 @default.
• W2979579528 hasAuthorship W2979579528A5068055759 @default.
• W2979579528 hasAuthorship W2979579528A5083951467 @default.
• W2979579528 hasConcept C126322002 @default.
• W2979579528 hasConcept C143998085 @default.
• W2979579528 hasConcept C2776364478 @default.
• W2979579528 hasConcept C2776694085 @default.
• W2979579528 hasConcept C2777478702 @default.
• W2979579528 hasConcept C2777525834 @default.
• W2979579528 hasConcept C2778367456 @default.
• W2979579528 hasConcept C2778559949 @default.
• W2979579528 hasConcept C2779338263 @default.
• W2979579528 hasConcept C502942594 @default.
• W2979579528 hasConcept C71924100 @default.
• W2979579528 hasConcept C98274493 @default.
• W2979579528 hasConceptScore W2979579528C126322002 @default.
• W2979579528 hasConceptScore W2979579528C143998085 @default.
• W2979579528 hasConceptScore W2979579528C2776364478 @default.
• W2979579528 hasConceptScore W2979579528C2776694085 @default.
• W2979579528 hasConceptScore W2979579528C2777478702 @default.
• W2979579528 hasConceptScore W2979579528C2777525834 @default.
• W2979579528 hasConceptScore W2979579528C2778367456 @default.
• W2979579528 hasConceptScore W2979579528C2778559949 @default.
• W2979579528 hasConceptScore W2979579528C2779338263 @default.
• W2979579528 hasConceptScore W2979579528C502942594 @default.
• W2979579528 hasConceptScore W2979579528C71924100 @default.
• W2979579528 hasConceptScore W2979579528C98274493 @default.
• W2979579528 hasLocation W29795795281 @default.
• W2979579528 hasOpenAccess W2979579528 @default.
• W2979579528 hasPrimaryLocation W29795795281 @default.
• W2979579528 hasRelatedWork W2077610119 @default.
• W2979579528 hasRelatedWork W2084647551 @default.
• W2979579528 hasRelatedWork W215417888 @default.
• W2979579528 hasRelatedWork W2248548669 @default.
• W2979579528 hasRelatedWork W2463427283 @default.
• W2979579528 hasRelatedWork W2497974852 @default.
• W2979579528 hasRelatedWork W2535357007 @default.
• W2979579528 hasRelatedWork W2549152338 @default.
• W2979579528 hasRelatedWork W2550354355 @default.
• W2979579528 hasRelatedWork W2556475996 @default.
• W2979579528 hasRelatedWork W2558650006 @default.
• W2979579528 hasRelatedWork W2560281006 @default.
• W2979579528 hasRelatedWork W2568855134 @default.
• W2979579528 hasRelatedWork W2573990768 @default.
• W2979579528 hasRelatedWork W2576915975 @default.
• W2979579528 hasRelatedWork W2583036110 @default.
• W2979579528 hasRelatedWork W2588640655 @default.
• W2979579528 hasRelatedWork W2602369513 @default.
• W2979579528 hasRelatedWork W2888048770 @default.
• W2979579528 hasRelatedWork W2980882990 @default.
• W2979579528 isParatext "false" @default.
• W2979579528 isRetracted "false" @default.
• W2979579528 magId "2979579528" @default.
• W2979579528 workType "article" @default.